Dexamethasone and COVID-19...
June 1, 2020 - Featured , In the News / Politics By: Natalia Loomis, PharmD Candidate c/o 2022 The World Health Organization announced the official name “COVID-19” on February 11, 2020 when the outbreak was first identified in Wuhan, China. ‘CO’ stands for ‘corona,’ ‘VI’ for ‘virus,’ and ‘D’ for disease and 19 for the year the first case occurred.2 The Center for Disease Control and… |
|
NIH COVID-19 Treatment Guidelines Update: remdesivir, c...
June 1, 2020 - Featured , In the News / Politics By: Jason Ifeanyi, PharmD Candidate c/o 2022 Severe acute respiratory syndrome 2 (Sars-Cov-2), the viral strain responsible for causing COVID-19, continues to have an undeniable impact both on a national level and a global level. As of June 20th, 2020, there have been nearly 2.4 million reported cases in the United States, with nearly 122,000… |
|
Usage of Ibuprofen and Angiotensin-Converting Enzyme In...
June 1, 2020 - Featured , Professional Advice / Opinions By: Evan Cheung, PharmD (c/o 2020) On March 11th, 2020, a research article was published in the Lancet journal that informed the public about a hypothesized issue regarding the use of ibuprofen in COVID-19 patients.1 Because of the information found in this article, patients and medical professions are wary of utilizing nonsteroidal anti-inflammatory drugs… |
|
When Epidemic Meets Pandemic: Treatment of Opioid Use D...
June 1, 2020 - Featured , In the News / Politics By: Preethi Samuel, PharmD Candidate c/o 2021, Aisa Mrkulic, PharmD. Candidate c/o 2022 Opioid use disorder (OUD) is a chronic illness involving misuse of opioids, both prescribed and non-prescribed, as well as the use of illicitly obtained heroin. OUD carries a risk of fatal overdose, preceded by the following triad: pinpoint pupils, respiratory depression,… |